CM
ZBIO

Capula Management’s Zenas BioPharma ZBIO Stock Holding History

Capula Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,615
Closed -$180K – 633
2024
Q3 		$180K Buy
+10,615
New +$191K ﹤0.01% 394

Other funds holding ZBIO

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capula Management's ZBIO Position: Q4 2024 in Review

Capula Management sold out of Zenas BioPharma (ZBIO) in Q4 2024, closing a stake of 10,615 shares — an estimated $180K sold.

Capula Management first reported a position in ZBIO in Q3 2024 and held it in 1 quarter. The position peaked at $180K in Q3 2024. 65 funds tracked by Wall St. Rank hold ZBIO as of Q4 2024.

  • Capula Management reported no remaining Zenas BioPharma position as of Q4 2024 after selling out during the quarter.
  • Capula Management sold 10,615 Zenas BioPharma shares in Q4 2024, an estimated $180K.
  • Capula Management first reported a position in Zenas BioPharma in Q3 2024 and held it in 1 quarter.
  • Capula Management's Zenas BioPharma position peaked at $180K in Q3 2024.
  • 65 funds tracked by Wall St. Rank held Zenas BioPharma as of Q4 2024.

Based on Capula Management's 13F filing for Q4 2024, filed 13 Feb 2025.